STAT+: Prometheus raises $12 billion in capital for artificial engineers

STAT PlusNewsletterThe Readout Prometheus raises $12 billion in capital for artificial engineers Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news Manage alerts for this article Email this article Share this article By Meghana KeshavanJune 12, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. AI continues to draw massive capital and new use cases in biopharma: Take Prometheus’ $12 billion raise to build “artificial general engineers,” or Abridge’s new partnerships with Eli Lilly and Nvidia, which aims in part to optimize the clinical trial recruitment process.Advertisement Plus, a nonprofit buys a shelved drug for a pediatric leukemia with plans to distribute it for free. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout LOUD June 11, 2026 An obesity drug deep-dive, and peptides move mainstream The Readout June 11, 2026 STAT Plus: Novartis doubles down on molecular glue strategy Advertisement Biotech June 11, 2026 STAT Plus: Enliven Therapeutics’ leukemia drug shows promise in new study Adam's Biotech Scorecard June 11, 2026 STAT Plus: ‘Synthetic lethality’ could trigger another round of biotech M&A The Readout June 10, 2026 STAT Plus: Hope for Kendall Square’s lab market Subscriber Picks